Approval for an additional AML indication for NS-17 (azacitidine)

An individual drug development program for NS-17 (azacitidine), covering a Phase 2 trial in acute myeloid leukemia, the regulatory application, and approval for an additional indication.

Companies1How many companies write about this.

Threads1One company can carry more than one thread here.

PeriodFY2018-Q3 →Last written FY2021

Directionhelps1 helps · 0 hurts · 0 flat

Loading